ERBB2 and breast cancer: Specifically, in the US cohort relative to the AB cohort, the proportion of TN breast cancer was higher (12.9% vs. 8.6%), and there were lower proportions of both HR+/HER2− breast cancer (49.2% vs. 60.5%), and HER2+ breast cancer (25.1% vs. 30.9%).